News
Hypotension during treatment with sacubitril/valsartan: practical tips for prevention and management
Despite the undeniable benefits of sacubitril/valsartan in terms of morbidity and mortality in patients with chronic heart failure, its administration can be complicated by side effects. The most common of these is hypotension. Although it is an unpleasant complication, it does not – and should not – always be a reason to discontinue therapy. Fear of hypotension should not lead to not prescribing sacubitril/valsartan at all. We provide practical guidance on how to approach this clinical situation.
Is it possible to predict survival time based on laboratory or radiological findings in patients with IPF?
High-resolution computed tomography (HRCT) imaging of the lungs is a fundamental examination in diagnosing idiopathic pulmonary fibrosis (IPF). According to experts from the Mayo Clinic, it can also…
Gliflozins in the Treatment of Type 2 Diabetes According to Current Recommendations SVL
Gliflozins are a relatively new group of antidiabetics with a specific mechanism of action. In addition to glycemic control, they have shown favorable effects on body weight and blood pressure,…
Combination of Arterial Hypertension and Increased Heart Rate as a Significant Cardiovascular Risk Factor
Heart rate is one of the basic vital signs that should be regularly measured. Sinus tachycardia can be physiological under certain conditions. However, a patient with resting tachycardia should…
Is Six Months of Adjuvant Targeted Therapy Sufficient for Early Breast Cancer?
The inclusion of adjuvant targeted therapy with chemotherapy for early HER2-positive breast cancer significantly improved patient outcomes. Since 2006, based on data from registration studies, the…
Targeted Treatment of Metastatic Breast Cancer in the 2nd Line – Experiences from Practice
The recommended treatment for metastatic HER2-positive breast cancer in the 1st line involves dual blockade of the HER2 signaling pathway using trastuzumab and pertuzumab in combination with a taxane…
Micronutrients in Parenteral Nutrition in Adult Patients – Current Issues and Consensus
Micronutrients are a key nutritional component, and this is also true for patients whose condition requires the administration of parenteral nutrition. An article published last year in the Journal…
Residual Pulmonary Hypertension After Endarterectomy: How Common Is It?
Pulmonary endarterectomy is the only potentially curative option in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). What are its outcomes and in what percentage of cases does…
Medium to Long-term Results of PFC Sigma Total Knee Arthroplasty
The PFC Sigma knee implant was introduced in 1997. It is the most commonly used system for total knee arthroplasty in England and Wales, accounting for 34.9% of primary implantations in 2006. Studies…
Venous Insufficiency of the Lower Extremities – A Diverse Range of Risks, Manifestations, and Complications
Although initially often asymptomatic, chronic venous insufficiency includes a variety of symptoms. Some of its manifestations can be irreversible, increasing the socio-economic burden that this…
Geriatrics and Nutrition in Old Age - Invitation
We invite you to watch a webinar dedicated to the topic of nutrition in old age. The impetus for its creation was the fact that from September 1, 2020, physicians specializing in geriatrics are allowed...
Effect of Zolpidem on the Quality of Overnight Sleep in Terms of Episodic Memory Formation
Zolpidem is a non-benzodiazepine hypnotic used for the short-term treatment of insomnia in adults. Previous studies have shown that this gamma-aminobutyric acid (GABA-A) agonist stimulates the…
Idiopathic Pulmonary Fibrosis: What Can a General Practitioner Do?
When a previously healthy patient becomes breathless, it's never good news. Among the particularly serious issues that breathlessness can signal is idiopathic pulmonary fibrosis (IPF). However, its…
Direct Oral Anticoagulants and Their Reversal Agents – Current Options
In the last 10 years, the options for anticoagulant therapy have expanded with the introduction of direct oral anticoagulants (DOACs). It appears that DOACs may soon replace warfarin in the first…
Two Is Not Enough: Efficacy of Alemtuzumab in Subsequent Cycles
The goal of the recent pooled analysis of the CARE-MS and TOPAZ study results published in the journal Multiple Sclerosis was to evaluate the efficacy and safety of alemtuzumab in patients with…
Popular this week
- Ambient artificial intelligence for clinical documentation: evidence, legislative framework and implementation in clinical practice
- Reproductive postponement as a clinical problem: biological limits, reproductive difficulties and psychosexual impact on the couple
- Frailty syndrome and type 2 diabetes – relationships and risks
- Terapia jąkania metodą Tarkowskiego